ライフサイエンスコーパス: mirtazapine

1 roup (67 [66%] of 102 participants receiving mirtazapine).

2 elective serotonin reuptake inhibitor and/or mirtazapine).

3 d a potentially higher mortality with use of mirtazapine.

4 osing opportunities, like the antidepressant mirtazapine.

5 flexible splines for SSRIs, venlafaxine, and mirtazapine.

6 n), (3) 1 mg/kg mirtazapine, or (4) 5 mg/ kg mirtazapine.

7 eased by the antidepressants desipramine and mirtazapine.

8 rence 1.17, 95% CI -0.23 to 2.58; p=0.10) or mirtazapine (0.01, -1.37 to 1.38; p=0.99), or between pa

9 In the telemetry model, mirtazapine (0.3-3 mg/kg, i.p.) caused an increase in TS

10 Administration of mirtazapine (1-3 mg/kg, i.p.) resulted in a slight decre

11 ndent model of thermoregulatory dysfunction, mirtazapine (10 mg/kg, i.p.) induced an increase in tail

12 lowed by a more modest increase, whereas for mirtazapine (11 treatment groups) efficacy increased up

13 ts were randomized in a 1:1 ratio to receive mirtazapine, 15 mg, or placebo for 2 weeks followed by a

14 atypical antidepressants (mianserin, 1.93%; mirtazapine, 22.87%).

15 Pretreatment with mirtazapine 24h prior to the CPP test had no effect on C

16 Random assignment to daily oral mirtazapine (30 mg) or placebo; both arms included 30-mi

17 for venlafaxine, 210.3 mg (SD=95.2); and for mirtazapine, 35.7 mg (SD=17.6).

18 ive sertraline (target dose 150 mg per day), mirtazapine (45 mg), or placebo (control group), all wit

19 Thirty participants were randomized to mirtazapine (7.5-45 mg/day) or placebo in a 2:1 ratio.

20 ty-seven percent of participants assigned to mirtazapine (95% CI 22%: 74%) and 20% assigned to placeb

21 ated drugs (aHR=1.29, 95% CI: 1.24-1.34) and mirtazapine (aHR=1.17, 95% CI: 1.07-1.29) were associate

22 To determine if mirtazapine altered the expression of MSn, on day 11, ra

23 bed medications such as antidepressants (eg, mirtazapine, amitriptyline) and antihyperglycemics such

24 We assessed the efficacy and safety of mirtazapine, an antidepressant prescribed for agitation

25 This study reports the effects of mirtazapine, an antidepressant with 5-HT(1) agonist as w

26 QIDS-SR(16) response rates were 13.4% for mirtazapine and 16.5% for nortriptyline.

27 tly different between participants receiving mirtazapine and participants receiving placebo (adjusted

28 differences in mean 10-week changes between mirtazapine and placebo occurred on any outcome measure.

29 ferences in adverse effect frequency between mirtazapine and placebo.

30 reated with the serotonin reuptake inhibitor mirtazapine and remains neurologically stable, with reso

31 .38; p=0.99), or between participants in the mirtazapine and sertraline groups (1.16, -0.25 to 2.57;

32 Overall, mirtazapine and venlafaxine users had the most adverse o

33 ) and atypical antidepressants (agomelatine, mirtazapine), and significant negative affective biases

34 maceuticals (efavirenz (EFV), acetaminophen, mirtazapine, and galantamine) prescribed for indications

35 ecently introduced: venlafaxine, nefazodone, mirtazapine, and reboxetine.

36 idepressant prescribing included sertraline, mirtazapine, and trazodone.

37 from 73% (22 of 30) to 44% (12 of 27) in the mirtazapine arm.

38 he data from this study do not support using mirtazapine as a treatment for agitation in dementia.

39 ments include amitriptyline, venlafaxine and mirtazapine, as well as some selected non-pharmacologica

40 With respect to saline injections, mirtazapine at all three doses reduced apnea index durin

41 In contrast, a 30min pretreatment of mirtazapine attenuated the expression of both CPP and MS

42 tidepressants (eg, nefazodone hydrochloride, mirtazapine, bupropion hydrochloride, and venlafaxine hy

43 posed candidate drugs, tramadol, olanzapine, mirtazapine, bupropion, and atomoxetine were associated

44 ovariectomized (OVX) rats has suggested that mirtazapine can alleviate thermoregulatory dysfunction b

45 This trial found no benefit of mirtazapine compared with placebo, and we observed a pot

46 significantly more among participants taking mirtazapine compared with those taking placebo (number o

47 st commonly prescribed drugs, sertraline and mirtazapine, compared with placebo.

48 Mirtazapine did not have significant efficacy on post-my

49 erapy, sertraline, escitalopram, citalopram, mirtazapine, duloxetine, trazodone, fluoxetine, bupropio

50 Mirtazapine, escitalopram, venlafaxine, and sertraline w

51 Mirtazapine exhibited potent functional antagonism (EC(5

52 , on day 11, rats received a pretreatment of mirtazapine, followed 30min later by a challenge injecti

53 blind, placebo-controlled trial-the Study of Mirtazapine for Agitated Behaviours in Dementia trial (S

54 ble-blind, placebo-controlled pilot trial of mirtazapine for anxiety in youth with autism spectrum di

55 was significantly higher in patients in the mirtazapine group (14.5 g vs 0.7 g; P = .02) after 8 wee

56 ertraline group (46 of 107, 43%; p=0.010) or mirtazapine group (44 of 108, 41%; p=0.031), and fewer s

57 of 102 controls) was similar to that in the mirtazapine group (67 [66%] of 102 participants receivin

58 re randomized to the placebo (n = 43) or the mirtazapine group (n = 43).

59 p=0.023), but not in a combined venlafaxine-mirtazapine group (n=140; accuracy 51.4%, p=0.53), sugge

60 However, there were more deaths in the mirtazapine group (n=7) by week 16 than in the control g

61 who received mirtazapine or placebo, but the mirtazapine group had a significant increase in energy i

62 treat analysis, participants assigned to the mirtazapine group had fewer methamphetamine-positive uri

63 The mirtazapine group significantly decreased the proportion

64 ine group and 13.7% for the venlafaxine plus mirtazapine group).

65 up and the extended-release venlafaxine plus mirtazapine group, and the rates were not statistically

66 Mirtazapine has been suggested as a feasible option in t

67 cific (5-HT1) serotonergic transmission, and mirtazapine has therefore been termed a noradrenergic an

68 pharmacotherapy was limited to paroxetine or mirtazapine in both MBC or standard care groups.

69 ine, citalopram, trazodone, telmisartan, and mirtazapine in eggs and yolk sac fry over time, followed

70 atment with extended-release venlafaxine and mirtazapine in patients with treatment-resistant major d

71 paroxetine, and sertraline), venlafaxine, or mirtazapine in the acute treatment of adults (aged 18 ye

72 The addition of mirtazapine in the treatment of patients with advanced N

73 ake inhibitors, nefazodone, venlafaxine, and mirtazapine) in participants younger than 19 years with

74 at the highest dose tested (10 mg/kg, i.p.), mirtazapine induced a small but significant decrease in

75 ting improved NREM sleep consolidation after mirtazapine injection.

76 cantly higher risk of discontinuation (e.g., mirtazapine: IRR=1.55, 95% CI=1.50-1.61; venlafaxine: IR

77 Mirtazapine is a potent antagonist of central 2alpha-adr

78 Mirtazapine is an atypical antidepressant receiving atte

79 at functional blockade of these receptors by mirtazapine is not a likely mechanism for restoring ther

80 injection of: (1) saline, (2) 0.1 mg/kg +/- mirtazapine (labeled as Remeron), (3) 1 mg/kg mirtazapin

81 Collectively, these results indicate that mirtazapine may help to maintain abstinence in opioid de

82 Antidepressant therapy with 15 to 45 mg/d of mirtazapine (n = 124) or 20 to 40 mg/d of paroxetine (n

83 (N=58) or extended-release venlafaxine plus mirtazapine (N=51).

84 cific (non-SSRI) antidepressants (bupropion, mirtazapine, nefazodone, and venlafaxine), tricyclic ant

85 etine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sert

86 , fluvoxamine, levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine, sertral

87 faxine, duloxetine, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, reboxetine, sertral

88 apine fumarate, amitriptyline hydrochloride, mirtazapine, nortriptyline hydrochloride, fluoxetine hyd

89 italopram oxalate, fluoxetine hydrochloride, mirtazapine, nortriptyline hydrochloride, paroxetine hyd

90 ive serotonin reuptake inhibitor [SSRI]) and mirtazapine (not an SSRI) in 246 elderly patients with m

91 y significant change in total PARS score for mirtazapine, numerically greater reduction in total PARS

92 esent study were to reexamine the effects of mirtazapine on temperature regulation in OVX rat models

93 we restricted the control group to users of mirtazapine only in a sensitivity analysis, the findings

94 in appetite scores in patients who received mirtazapine or placebo after 4 and 8 weeks.

95 appetite scores in all patients who received mirtazapine or placebo, but the mirtazapine group had a

96 irtazapine (labeled as Remeron), (3) 1 mg/kg mirtazapine, or (4) 5 mg/ kg mirtazapine.

97 We conclude that mirtazapine, over a 50-fold dose range, significantly re

98 of NREM sleep was unaffected by any dose of mirtazapine (p = 0.42), but NREM EEG delta power was inc

99 opram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, and ven

100 as tested on day 10 following a 24h or 30min mirtazapine pretreatment.

101 t greater than 50% of participants receiving mirtazapine rated as responders).

102 For mirtazapine, remission rates were 12.3% and 8.0% per the

103 Mirtazapine resulted in a statistically significant with

104 To examine this finding further, mirtazapine's effect on CBT was determined.

105 The results are consistent with mirtazapine's safety and tolerability and meet three of

106 Mirtazapine, sertraline, fluoxetine, buspirone, and agom

107 We propose that mirtazapine should be investigated further for use in PM

108 Both venlafaxine and mirtazapine showed optimal acceptability in the lower ra

109 ast, HTR2A 102 T/C genotype had no effect on mirtazapine side effects.

110 After 4 weeks, mirtazapine significantly increased energy intake (379.3

111 rictions, and ease of use of venlafaxine and mirtazapine suggest that this combination may be preferr

112 antidepressants mianserin, setiptiline, and mirtazapine suggests a mechanism for their clinically ob

113 , numerically higher number of responders to mirtazapine than placebo, but not greater than 50% of pa

114 ly greater reduction in total PARS score for mirtazapine than placebo, numerically higher number of r

115 re randomly assigned (1:1) to receive either mirtazapine (titrated to 45 mg) or placebo.

116 urrent investigation assessed the ability of mirtazapine to ameliorate morphine-induced behaviors.

117 present study evaluated the effectiveness of mirtazapine to reduce both behaviors.

118 The addition of mirtazapine to substance use counseling decreased metham

119 study compared the efficacy of switching to mirtazapine to that of switching to a tricyclic antidepr

120 Patients on mirtazapine tolerated the treatment well, but reported a

121 Results from mirtazapine-treated patients indicate that the effect of

122 Among mirtazapine-treated patients, there was little indicatio

123 Surprisingly, among mirtazapine-treated subjects, S allele carriers had fewe

124 domly assigned to 14 weeks of treatment with mirtazapine (up to 60 mg/day) (N=114) or nortriptyline (

125 The improvement in PARS score for mirtazapine versus placebo was clinically meaningful but

126 eived citalopram, fluoxetine, sertraline, or mirtazapine were randomly assigned in a 1:1 ratio to mai